Having trouble accessing articles? Reset your cache.

Brentuximab vedotin: Phase II data

Top-line data from a single-arm, open-label, international, pivotal Phase II trial in 102 patients who previously received an autologous stem cell transplant showed that brentuximab vedotin produced

Read the full 270 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE